Latest News
 
For the Leaders
 
Contact Us
 
 
 
 
 
 
Here’s what you need to be aware of:
 
 
 
 
 
FDA Grants Orphan Drug Designation to Elixirgen’s Gene Therapy for Rare Disease
 
 
Elixirgen Therapeutics, a clinical-stage biotech company, develops therapies to treat rare diseases. Its gene therapy, EXG-34217, is used to treat Telomere Biology Disorders.
 
 
 
Sandoz Launches Pyzchiva® in the US, Expanding Biosimilar Access
 
 
Sandoz is a global leader in generic and biosimilar medicines. By officially launching Pyzchiva® in the US, it successfully expanded access to affordable biologic treatments.
 
 
 
Chugai’s Tecentriq® Receives Approval in Japan for Unresectable Alveolar Soft Part Sarcoma
 
 
Chugai developed Tecentriq® to treat unresectable alveolar soft part sarcoma. It is the first immune checkpoint inhibitor available in Japan for this rare and aggressive cancer.
 
 
 
 
 
Navigate the Digital Frontier with Pharma Now!
 
 
Check the cover story
“SMART Practices to Take Assistance of Generative AI to Respond to FDA Warnings”
 
 
 
 
 
 
 
 
In this exclusive interview, she shares her bold career shift and lessons from managing 40,000+ employees across industries. Discover how she balances 7,000+ employees, keeps real connections alive in HR, and sustains a 100-year-old company’s culture.
 
Watch Now
 
 
 
 
 
Are you attending Pittcon 2025?
 
 
Pittcon 2025 is set to take place in San Diego, CA, from March 1-5. This event combines scientific sessions, technical workshops, and poster presentations and caters to professionals in analytical chemistry, spectroscopy, and related fields.
 
 
 
 
 
Until then, Adios!
 
Find us on:
 
       
Visit Pharma Now
 
2025 Pharma Now, All rights reserved
Subscribe
| Terms & Privacy |
Contact Us